A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Summary

This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.

Timeline

Start

2021-06-09

Primary completion

2024-04-30

Completion

2025-12-30

Outcome

Outcome not reported

Stopped: “Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”

Drugs

Indications